Trial Profile
A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; HMG-CoA reductase inhibitors
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms VYCTORY
- Sponsors Organon
- 03 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 20 Sep 2012 Planned initiation date changed from 1 Sep 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 20 Sep 2012 Planned End Date changed from 1 Jan 2014 to 1 May 2014 as reported by ClinicalTrials.gov.